Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2018 | Prognostic markers and MRD in CLL

Robin Foà • 25 Oct 2018
ERIC 2018
Chronic Lymphocytic Leukemia Leukemia

Speaking from the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) International Meeting 2018, held in Barcelona, Spain, Robin Foà, MD, of the Sapienza University of Rome, Rome, Italy, discusses the key prognostic markers and measurable residual disease in chronic lymphocytic leukemia.

More from Robin Foà

8:11
The José Carreras award and a history of immunotherapy in Ph+ ALL
Robin Foà • 11 Jun 2023
3:22
The evolution of therapy for Ph+ ALL and Ph- ALL & the role of MRD in this space
Robin Foà • 11 Jun 2023
2:36
Investigating the incidence and outcomes of CNS relapse in patients with ALL
Robin Foà • 23 Mar 2023
10:05
Chemotherapy-free regimens in Ph+ ALL: where are we now and where are we headed?
Robin Foà • 23 Mar 2023

Related Videos

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals